Drug Combination Details
| General Information of the Combination (ID: C69848) | |||||
|---|---|---|---|---|---|
| Name | Calycosin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | SIRT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | H9c2(2-1) | CVCL_0286 | Healthy | Rattus norvegicus | ||
| In-vivo Model | Male Kunming mice (8- 10 weeks old; body weight: 22 +/- 2 g) were used to construct a short-term model of cardiomyopathy. | |||||
| Experimental
Result(s) |
Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway. | |||||